FDA considers limiting authorization of certain monoclonal antibody treatments

Get the Full StoryFederal regulators are considering limiting the authorization of certain monoclonal antibody treatments that have not proved effective against the Omicron variant of the coronavirus, a source familiar with the decision-making told CNN.

Share: